Pfizer and BMS to give Eliquis a rolling launch in Europe

pharmafile | May 24, 2011 | News story | Sales and Marketing |ย ย Eliquis, Pfizer, apixaban, atrial fibrillationย 

Pfizer and Bristol-Myers Squibb are gearing up to give their new oral anticoagulant Eliquis a rolling launch in Europe, starting next week.

The newly-approved drug will be made available to prescribers first in Germany, Austria, Denmark and Poland, with additional national launches planned throughout June, A Pfizer spokesman told Pharmafocus.

Eliquis (apixaban) has just been approved in Europe for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

Once launched it will be up against two established VTE drugs, Boehringer Ingelheimโ€™s Pradaxa (dabigatran) and Bayerโ€™s Xarelto (rivaroxaban).

Advertisement

Both products are looking to expand their licences and in April Pradaxa was recommended by European regulatory advisors for a new indication as a preventative treatment for stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Bayer is also seeking to gain the same indication for its drug and is hoping for a decision from the EMA by the third quarter, having submitted Xarelto in January.

Pfizer said it too will be looking to expand Eliquisโ€™ licence and that results from an ongoing phase III trial for AF stroke prevention โ€“ expected later this year – would form the basis of a new filing for the drug.

Ben Adams

Related Content

NICE recommends Pfizerโ€™s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21stย May 2025ย โ€“ย Pfizer Ltd announced today that the National Institute for Health and Care …

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …

The Gateway to Local Adoption Series

Latest content